Merit Medical Launches Resilience TTS Esophageal Stent for Cancer-Related Strictures and Fistulas
Key Insights
Merit Medical Systems (search) has launched the Resilience Through-the-Scope Esophageal Stent in the U.S., designed to treat esophageal fistulas (search) and malignant strictures (search) caused by cancerous tumors.
The device features proprietary anti-migration flanges and a single-handed delivery system, offering enhanced stability and precision compared to existing TTS esophageal stents.
The stent is available in three size configurations (14mm×50mm, 17mm×50mm, and 20mm×50mm) to accommodate diverse clinical requirements and patient care needs.
Merit Medical Systems (search) has announced the U.S. commercial launch of its Resilience Through-the-Scope (TTS) Esophageal Stent, marking a significant advancement in treating esophageal conditions. The device is specifically designed to address esophageal fistulas (search) and malignant strictures (search) caused by cancerous tumors, expanding the company's endoscopy portfolio with innovative treatment options for patients facing these challenging conditions.
Addressing Critical Clinical Needs
Esophageal cancer (search) remains the sixth leading cause of cancer-related deaths globally, with patients frequently experiencing debilitating symptoms including difficulty swallowing, regurgitation, and chest discomfort. The Resilience stent represents a targeted response to these clinical challenges, engineered to overcome several common limitations associated with existing TTS esophageal stents.
The device incorporates proprietary anti-migration flanges that help secure it in place, offering strong resistance to movement compared with other existing TTS stents. This enhanced stability addresses a critical concern in esophageal stent placement, where device migration can compromise treatment effectiveness and patient outcomes.
Advanced Design Features
The Resilience stent features a single-handed delivery system, allowing clinicians to place it with greater precision and ease. This design improvement streamlines the placement procedure and potentially reduces procedural complexity for healthcare providers.
To accommodate diverse clinical requirements, the Resilience stent is available in multiple size configurations: 14 mm × 50 mm, 17 mm × 50 mm, and 20 mm × 50 mm, offering greater flexibility in patient care. This range of sizing options enables clinicians to select the most appropriate device for individual patient anatomy and clinical presentation.
According to Dr. Stuart K. Amateau, MD, PhD, Professor and Chief of the Division of Gastroenterology, Hepatology, and Nutrition at the University of Minnesota Medical Center in Minneapolis, MN, "The Resilience TTS Esophageal Stent (search) addresses an unmet clinical need with its distinctive size options, advanced design, easy-to-use delivery system and anti-migration features."
Market Impact and Growth Prospects
The launch strengthens Merit Medical's competitive positioning in the gastrointestinal and endoscopy markets by expanding its product portfolio and addressing unmet clinical needs. The company's differentiated features, including enhanced anti-migration design, unique size offerings, and ease of deployment, position the device to drive higher adoption among clinicians.
According to Intel Market Research data, the esophageal stent market is valued at $345 million in 2026 and is expected to witness a compound annual growth rate of 5.3% through 2034. Market growth is being driven by factors including the growing incidence of esophageal cancer (search) and benign strictures, as well as technological innovations in stent materials and designs, including biodegradable polymers and drug-eluting coatings.
Company Performance and Strategic Context
Merit Medical Systems (search), with a current market capitalization of $4.11 billion, has seen shares gain 1.5% since the announcement. The innovation is expected to boost revenue growth and reinforce the company's reputation for delivering advanced, patient-focused solutions, ultimately supporting long-term market share expansion.
The company recently reported positive results from the randomized AVF arm of the WAVE trial in November, which were presented during a Late-Breaking Clinical Trials session at the Vascular Interventional Advances (VIVA) conference. Merit Medical also shared 24-month efficacy data from the non-randomized AVG cohort of the WAVE trial at the annual VIVA Foundation Venous Endovascular Interventional Strategies conference.